Synergistic Antimicrobial Activity Between the Broad Spectrum Bacteriocin Garvicin KS and Nisin, Farnesol and Polymyxin B Against Gram-Positive and Gram-Negative Bacteria
Tóm tắt
The increasing emergence of antibiotics resistance is of global concern. Finding novel antimicrobial agents and strategies based on synergistic combinations are essential to combat resistant bacteria. We evaluated the activity of garvicin KS, a new bacteriocin produced by Lactococcus garvieae. The bacteriocin has a broad inhibitory spectrum, inhibiting members of all the 19 species of Gram-positive bacteria tested. Unlike other bacteriocins from Gram-positive bacteria, garvicin KS inhibits Acinetobacter but not other Gram-negative bacteria. Garvicin KS was tested in combination with other antimicrobial agents. We demonstrated synergy with polymyxin B against Acinetobacter spp. and Escherichia coli, but not against Pseudomonas aeruginosa. Similar effects were seen with mixtures of nisin and polymyxin B. The synergistic mixtures of all three components caused rapid killing and full eradication of Acinetobacter spp. and E. coli. In addition, garvicin KS and nisin also acted synergistically against Staphylococcus aureus, indicating different in modes of action between the two bacteriocins. Both bacteriocins showed synergy with farnesol, and the combination of low concentrations of garvicin KS, nisin and farnesol caused rapid eradication of all the S. aureus strains tested. Its broad inhibitory spectrum, rapid killing, and synergy with other antimicrobials makes garvicin KS a promising antimicrobial.
Tài liệu tham khảo
Arques JL, Rodriguez E, Langa S, Landete JM, Medina M (2015) Antimicrobial activity of lactic acid bacteria in dairy products and gut: effect on pathogens. Biomed Res Int 2015:584183. doi:10.1155/2015/584183
Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, Nation RL, Li J, Tsuji BT (2015) Optimizing polymyxin combinations against resistant Gram-negative bacteria. Infect Dis Ther 4(4):391–415. doi:10.1007/s40121-015-0093-7
Bhusal Y, Shiohira CM, Yamane N (2005) Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents 26(4):292–297. doi:10.1016/j.ijantimicag.2005.05.005
Bollenbach T (2015) Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol 27:1–9. doi:10.1016/j.mib.2015.05.008
Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D (2012) Ready for a world without antibiotics? The pensieres antibiotic resistance call to action. Antimicrob Resist Infect Control 1(1):11. doi:10.1186/2047-2994-1-11
Cotter PD, Ross RP, Hill C (2013) Bacteriocins—a viable alternative to antibiotics? Nat Rev Microbiol 11(2):95–105. doi:10.1038/nrmicro2937
Delcour AH (2009) Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 1794(5):808–816. doi:10.1016/j.bbapap.2008.11.005
Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici De Angelis L, Fortunato S, Giani T, Menichetti F, Rossolini GM (2016) mcr-1.2, a new mcr variant carried on a transferable plasmid from a colistin-resistant KPC carbapenemase-producing Klebsiella pneumoniae strain of sequence type 512. Antimicrob Agents Chemother 60(9):5612–5615. doi:10.1128/aac.01075-16
Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10(1):R27. doi:10.1186/cc3995
Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A (2008) Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32(5):450–454. doi:10.1016/j.ijantimicag.2008.05.016
Field D, Cotter PD, Ross RP, Hill C (2015) Bioengineering of the model lantibiotic nisin. Bioengineered 6(4):187–192. doi:10.1080/21655979.2015.1049781
Field D, O’ Connor R, Cotter PD, Ross RP, Hill C (2016) In vitro activities of nisin and nisin derivatives alone and in combination with antibiotics against Staphylococcus biofilms. Front Microbiol 7 (508). doi:10.3389/fmicb.2016.00508
Field D, Seisling N, Cotter PD, Ross RP, Hill C (2016) Synergistic nisin-polymyxin combinations for the control of Pseudomonas biofilm formation. Front Microbiol 7:1713. doi:10.3389/fmicb.2016.01713
Gao Y, van Belkum MJ, Stiles ME (1999) The outer membrane of Gram-negative bacteria inhibits antibacterial activity of brochocin-C. Appl Environ Microbiol 65(10):4329–4333
Gomes F, Leite B, Teixeira P, Cerca N, Azeredo J, Oliveira R (2011) Farnesol as antibiotics adjuvant in Staphylococcus epidermidis control in vitro. Am J Med Sci 341(3):191–195. doi:10.1097/MAJ.0b013e3181fcf138
Holo H, Nilssen O, Nes IF (1991) Lactococcin A, a new bacteriocin from Lactococcus lactis subsp. cremoris: isolation and characterization of the protein and its gene. J Bacteriol 173(12):3879–3887
Jabra-Rizk MA, Meiller TF, James CE, Shirtliff ME (2006) Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 50(4):1463–1469. doi:10.1128/aac.50.4.1463-1469.2006
Kostoulias X, Murray GL, Cerqueira GM, Kong JB, Bantun F, Mylonakis E, Khoo CA, Peleg AY (2016) Impact of a cross-kingdom signaling molecule of Candida albicans on Acinetobacter baumannii physiology. Antimicrob Agents Chemother 60(1):161–167. doi:10.1128/aac.01540-15
Mathur H, Field D, Rea MC, Cotter PD, Hill C, Ross RP (2017) Bacteriocin-antimicrobial synergy: a medical and food perspective. Front Microbiol 8:1205. doi:10.3389/fmicb.2017.01205
Naghmouchi K, Baah J, Hober D, Jouy E, Rubrecht C, Sane F, Drider D (2013) Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob Agents Chemother 57(6):2719–2725. doi:10.1128/aac.02328-12
Naghmouchi K, Drider D, Baah J, Teather R (2010) Nisin A and polymyxin B as synergistic inhibitors of Gram-positive and Gram-negative bacteria. Probiotics Antimicrob Proteins 2(2):98–103. doi:10.1007/s12602-009-9033-8
Neu HC, Fu KP (1978) Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins. Antimicrob Agents Chemother 13(5):813–819
Ouderkirk JP, Nord JA, Turett GS, Kislak JW (2003) Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 47(8):2659–2662
Ovchinnikov KV, Chi H, Mehmeti I, Holo H, Nes IF, Diep DB (2016) Novel group of leaderless multipeptide bacteriocins from Gram-positive bacteria. Appl Environ Microbiol 82(17):5216–5224. doi:10.1128/aem.01094-16
Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK, Park DW, Lee HJ, Lee MS, Ko KS (2012) In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. J Med Microbiol 61(Pt 3):353–360. doi:10.1099/jmm.0.036939-0
Siddiqui NU, Qamar FN, Jurair H, Haque A (2014) Multi-drug resistant Gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. BMC Infect Dis 14:626. doi:10.1186/s12879-014-0626-9
Steckbeck JD, Deslouches B, Montelaro RC (2014) Antimicrobial peptides: new drugs for bad bugs? Expert Opin Biol Ther 14(1):11–14. doi:10.1517/14712598.2013.844227
Stevens KA, Sheldon BW, Klapes NA, Klaenhammer TR (1991) Nisin treatment for inactivation of Salmonella species and other Gram-negative bacteria. Appl Environ Microbiol 57(12):3613–3615
Zavascki AP, Goldani LZ, Li J, Nation RL (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60(6):1206–1215. doi:10.1093/jac/dkm357
Zendo T (2013) Screening and characterization of novel bacteriocins from lactic acid bacteria. Biosci Biotechnol Biochem 77(5):893–899. doi:10.1271/bbb.130014